8.50
0.03 (0.35%)
| Previous Close | 8.47 |
| Open | 8.49 |
| Volume | 3,144,131 |
| Avg. Volume (3M) | 4,029,720 |
| Market Cap | 790,899,520 |
| Price / Sales | 3.61 |
| Price / Book | 6.58 |
| 52 Weeks Range | |
| Earnings Date | 21 Mar 2025 |
| Operating Margin (TTM) | -43,073.68% |
| Diluted EPS (TTM) | -0.990 |
| Quarterly Revenue Growth (YOY) | 1,325.00% |
| Total Debt/Equity (MRQ) | 0.97% |
| Current Ratio (MRQ) | 5.70 |
| Operating Cash Flow (TTM) | -74.98 M |
| Levered Free Cash Flow (TTM) | -44.05 M |
| Return on Assets (TTM) | -33.64% |
| Return on Equity (TTM) | -56.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Chimerix, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.38 |
|
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.73% |
| % Held by Institutions | 56.44% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 29.41%) | Hold |
| Median | 8.55 (0.59%) | |
| Low | 8.50 (Jefferies, 0.00%) | Hold |
| Average | 9.35 (10.00%) | |
| Total | 3 Hold | |
| Avg. Price @ Call | 8.45 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 06 Mar 2025 | 8.55 (0.59%) | Hold | 8.43 |
| HC Wainwright & Co. | 05 Mar 2025 | 11.00 (29.41%) | Hold | 8.46 |
| 18 Feb 2025 | 11.00 (29.41%) | Buy | 4.83 | |
| Jefferies | 05 Mar 2025 | 8.50 (0.00%) | Hold | 8.46 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |